Abstract
Under the guidance of our previous work, we synthesized 21 new structures of quinazolines (3a~3u) and evaluated their in vitro anticancer activity against A549, HCT116 and MCF-7 cell lines using the MTT method. Most compounds showed good to excellent anticancer activity. In particular, 3o (regarded as erlotinib analogues) has marked anticancer activity against A549, HCT116 and MCF-7 cell lines (IC50s: 4.26, 3.92 and 0.14 μM, respectively) as compared with the standard anticancer drug gefitinib (IC50s: 17.9, 21.55 and 20.68 μM, respectively), and which can be regarded as the best candidate for development of anticancer drugs.
Keywords: Anticancer evaluation, quinazoline derivatives, synthesis.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Synthesis and Biological Evaluation of Quinazoline Derivatives as Potential Anticancer Agents (II)
Volume: 15 Issue: 10
Author(s): Jianping Yong, Canzhong Lu and Xiaoyuan Wu
Affiliation:
Keywords: Anticancer evaluation, quinazoline derivatives, synthesis.
Abstract: Under the guidance of our previous work, we synthesized 21 new structures of quinazolines (3a~3u) and evaluated their in vitro anticancer activity against A549, HCT116 and MCF-7 cell lines using the MTT method. Most compounds showed good to excellent anticancer activity. In particular, 3o (regarded as erlotinib analogues) has marked anticancer activity against A549, HCT116 and MCF-7 cell lines (IC50s: 4.26, 3.92 and 0.14 μM, respectively) as compared with the standard anticancer drug gefitinib (IC50s: 17.9, 21.55 and 20.68 μM, respectively), and which can be regarded as the best candidate for development of anticancer drugs.
Export Options
About this article
Cite this article as:
Yong Jianping, Lu Canzhong and Wu Xiaoyuan, Synthesis and Biological Evaluation of Quinazoline Derivatives as Potential Anticancer Agents (II), Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (10) . https://dx.doi.org/10.2174/1871520615666150526115904
DOI https://dx.doi.org/10.2174/1871520615666150526115904 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metronomic Therapy for Multi Relapsed/Refractory Lymphoma. A Pilot Study
Current Angiogenesis (Discontinued) Trafficking Potentials of Unconventional T Cell Subsets
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents DEFB1 5'UTR Polymorphisms Modulate the Risk of HIV-1 Infection in Mexican Women
Current HIV Research Current Concepts for the Combined Treatment Modality of Ionizing Radiation with Anticancer Agents
Current Pharmaceutical Design Characterization of Gemcitabine Loaded Polyhydroxybutyrate Coated Magnetic Nanoparticles for Targeted Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Classification of Benign and Malignant Breast Masses on Mammograms for Large Datasets using Core Vector Machines
Current Medical Imaging Peroxisome Proliferator-Activated Receptors and the Control of Inflammation
Current Drug Targets - Inflammation & Allergy Synthesis of Fluorescent Cysteine-gold Nano-clusters (Cys-Au-NCs) and their Application as Nano-biosensors for the Determination of Cysteine
Current Nanoscience Polymeric Nanoparticles of Aromatase Inhibitors: A Comprehensive Review
Current Pharmaceutical Design Pharmacophore Based 3D-QSAR Study of Biphenyl Derivatives as Nonsteroidal Aromatase Inhibitors in JEG-3 Cell Lines
Medicinal Chemistry Preparation and Evaluation of in vitro Self-assembling HSA Nanoparticles for Cabazitaxel
Anti-Cancer Agents in Medicinal Chemistry Protective Role of Natural Products in Cisplatin-Induced Nephrotoxicity
Mini-Reviews in Medicinal Chemistry Disintegrins
Current Drug Targets - Cardiovascular & Hematological Disorders Failure of Ditiocarb (Diethyldithiocarbamate) Therapy: Was Diet the Reason?
Current HIV Research Development ofNovel Compounds to Treat Autoimmune and Inflammatory Diseases and Graft Versus Host Reactions
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial [Hot Topic: Anticancer Platinum Complexes - State of the Art and Future Prospects (Guest Editor: Markus Galanski)]
Anti-Cancer Agents in Medicinal Chemistry Cell Hierarchy, Metabolic Flexibility and Systems Approaches to Cancer Treatment
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Genomic Applications to Various Biological Questions)
Current Genomics Current Concepts on the Management of Chordoma
Current Drug Therapy Role of NF-κB and NF-κB-regulated Gene Products in Chemoresistance and Radioresistance
Current Cancer Therapy Reviews